Ionis Pharmaceuticals Past Earnings Performance
Past criteria checks 0/6
Ionis Pharmaceuticals's earnings have been declining at an average annual rate of -38.3%, while the Biotechs industry saw earnings growing at 7.7% annually. Revenues have been declining at an average rate of 5.4% per year.
Key information
-38.3%
Earnings growth rate
-37.9%
EPS growth rate
| Biotechs Industry Growth | -14.6% |
| Revenue growth rate | -5.4% |
| Return on equity | -54.2% |
| Net Margin | -44.7% |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Ionis Pharmaceuticals makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 803 | -359 | 230 | 3 |
| 30 Jun 24 | 813 | -366 | 239 | 0 |
| 31 Mar 24 | 777 | -385 | 220 | 0 |
| 31 Dec 23 | 788 | -366 | 213 | 0 |
| 30 Sep 23 | 615 | -409 | 210 | 586 |
| 30 Jun 23 | 631 | -309 | 174 | 0 |
| 31 Mar 23 | 576 | -329 | 162 | 0 |
| 31 Dec 22 | 587 | -270 | 150 | 0 |
| 30 Sep 22 | 875 | 7 | 141 | 0 |
| 30 Jun 22 | 849 | -28 | 137 | 0 |
| 31 Mar 22 | 841 | -4 | 148 | 0 |
| 31 Dec 21 | 810 | -29 | 186 | 0 |
| 30 Sep 21 | 661 | -608 | 207 | 0 |
| 30 Jun 21 | 688 | -550 | 245 | 0 |
| 31 Mar 21 | 708 | -495 | 272 | 0 |
| 31 Dec 20 | 729 | -444 | 354 | 0 |
| 30 Sep 20 | 933 | 94 | 299 | 0 |
| 30 Jun 20 | 940 | 145 | 290 | 0 |
| 31 Mar 20 | 959 | 169 | 293 | 0 |
| 31 Dec 19 | 1,123 | 281 | 287 | 0 |
| 30 Sep 19 | 821 | 433 | 269 | 0 |
| 30 Jun 19 | 799 | 402 | 278 | 0 |
| 31 Mar 19 | 752 | 366 | 269 | 0 |
| 31 Dec 18 | 600 | 277 | 245 | 0 |
| 30 Sep 18 | 575 | -41 | 224 | 0 |
| 30 Jun 18 | 548 | -38 | 182 | 0 |
| 31 Mar 18 | 543 | 9 | 138 | 0 |
| 31 Dec 17 | 514 | 19 | 108 | 0 |
| 30 Sep 17 | 507 | 42 | 81 | 0 |
| 30 Jun 17 | 499 | 52 | 64 | 0 |
| 31 Mar 17 | 426 | -15 | 52 | 0 |
| 31 Dec 16 | 373 | -60 | 49 | 0 |
| 30 Sep 16 | 238 | -184 | 44 | 0 |
| 30 Jun 16 | 176 | -227 | 42 | 0 |
| 31 Mar 16 | 258 | -134 | 40 | 0 |
| 31 Dec 15 | 284 | -88 | 37 | 0 |
| 30 Sep 15 | 317 | 14 | 31 | 0 |
| 30 Jun 15 | 312 | 23 | 27 | 0 |
| 31 Mar 15 | 249 | -24 | 23 | 0 |
| 31 Dec 14 | 214 | -39 | 20 | 0 |
| 30 Sep 14 | 172 | -94 | 18 | 0 |
| 30 Jun 14 | 151 | -92 | 17 | 0 |
| 31 Mar 14 | 132 | -90 | 16 | 0 |
| 31 Dec 13 | 147 | -61 | 15 | 0 |
Quality Earnings: ISI is currently unprofitable.
Growing Profit Margin: ISI is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: ISI is unprofitable, and losses have increased over the past 5 years at a rate of 38.3% per year.
Accelerating Growth: Unable to compare ISI's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: ISI is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-18.2%).
Return on Equity
High ROE: ISI has a negative Return on Equity (-54.16%), as it is currently unprofitable.